Published in Cell on July 11, 2008
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med (2011) 6.85
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov (2009) 4.12
Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer (2009) 4.06
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
p53 polymorphisms: cancer implications. Nat Rev Cancer (2009) 3.33
Transcriptional regulation by p53. Cold Spring Harb Perspect Biol (2010) 3.16
p53--a Jack of all trades but master of none. Nat Rev Cancer (2009) 2.96
CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest (2011) 2.90
Basal dynamics of p53 reveal transcriptionally attenuated pulses in cycling cells. Cell (2010) 2.40
Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene (2009) 2.32
Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature (2013) 2.29
A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol (2011) 2.19
Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res (2013) 1.84
BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol (2010) 1.76
Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol (2012) 1.75
Oncogene-like induction of cellular invasion from centrosome amplification. Nature (2014) 1.72
TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat Cell Biol (2013) 1.61
More than markers: biological significance of cancer stem cell-defining molecules. Mol Cancer Ther (2010) 1.60
Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest (2014) 1.58
Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma. BMC Cancer (2010) 1.55
p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome. Genes Cancer (2011) 1.54
CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res (2010) 1.52
Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell (2014) 1.49
The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res (2010) 1.44
Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines. Breast Cancer Res (2009) 1.42
Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res (2010) 1.38
Dynamic actin remodeling during epithelial-mesenchymal transition depends on increased moesin expression. Mol Biol Cell (2011) 1.38
Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res (2010) 1.37
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A (2011) 1.36
Reciprocal repression between P53 and TCTP. Nat Med (2011) 1.35
ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res (2011) 1.34
Contribution of p53 to metastasis. Cancer Discov (2014) 1.28
TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. Mol Cell Biol (2011) 1.25
The transcription factor p53: not a repressor, solely an activator. Cell Cycle (2014) 1.23
Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci (2012) 1.15
Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem (2011) 1.14
One function--multiple mechanisms: the manifold activities of p53 as a transcriptional repressor. J Biomed Biotechnol (2011) 1.14
53BP1 and USP28 mediate p53 activation and G1 arrest after centrosome loss or extended mitotic duration. J Cell Biol (2016) 1.12
A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer. Mol Pharmacol (2010) 1.12
p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. Proc Natl Acad Sci U S A (2014) 1.08
Metabostemness: a new cancer hallmark. Front Oncol (2014) 1.05
A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. Sci Signal (2013) 1.04
Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia. Cancer Res (2010) 1.04
p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell (2014) 1.04
Fish oil prevents breast cancer cell metastasis to bone. Biochem Biophys Res Commun (2010) 1.01
Effects of hyaluronic acid on mitochondrial function and mitochondria-driven apoptosis following oxidative stress in human chondrocytes. J Biol Chem (2009) 1.01
Therapeutic targeting of the p53 pathway in cancer stem cells. Expert Opin Ther Targets (2012) 1.01
p53-mediated heterochromatin reorganization regulates its cell fate decisions. Nat Struct Mol Biol (2012) 1.00
Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Res (2011) 0.99
Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target. Stem Cells Transl Med (2015) 0.99
Cabin1 restrains p53 activity on chromatin. Nat Struct Mol Biol (2009) 0.99
DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res (2009) 0.97
Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells. Mol Cancer (2010) 0.96
Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer. PLoS One (2013) 0.96
p53 regulates Period2 expression and the circadian clock. Nat Commun (2013) 0.94
Hyaluronan - a functional and structural sweet spot in the tissue microenvironment. Front Immunol (2015) 0.93
The impact of post-transcriptional regulation in the p53 network. Brief Funct Genomics (2012) 0.89
Transient p53 suppression increases reprogramming of human fibroblasts without affecting apoptosis and DNA damage. Stem Cell Reports (2014) 0.89
Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for both markers. J Histochem Cytochem (2011) 0.89
Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts. Int J Oncol (2010) 0.89
A pilot genome wide association and gene expression array study of suicide with and without major depression. World J Biol Psychiatry (2011) 0.89
HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget (2015) 0.89
Glycosaminoglycans and glucose prevent apoptosis in 4-methylumbelliferone-treated human aortic smooth muscle cells. J Biol Chem (2011) 0.88
DNA damage causes TP53-dependent coupling of self-renewal and senescence pathways in embryonal carcinoma cells. Cell Cycle (2012) 0.88
MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism. Cancer Res (2014) 0.88
Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice. Am J Pathol (2010) 0.87
Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells. PLoS One (2011) 0.87
Novel Perspectives on p53 Function in Neural Stem Cells and Brain Tumors. J Oncol (2010) 0.86
CD44 promotes Kras-dependent lung adenocarcinoma. Oncogene (2012) 0.86
Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer. Genet Epigenet (2015) 0.85
Therapeutic targeting of hyaluronan in the tumor stroma. Cancers (Basel) (2012) 0.85
Obesity, independent of p53 gene dosage, promotes mammary tumor progression and upregulates the p53 regulator microRNA-504. PLoS One (2013) 0.84
Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer. Clin Cancer Res (2015) 0.83
Multiplex enhancer-reporter assays uncover unsophisticated TP53 enhancer logic. Genome Res (2016) 0.83
CD44 expression in intestinal epithelium and colorectal cancer is independent of p53 status. PLoS One (2013) 0.83
Chronic UVR causes increased immunostaining of CD44 and accumulation of hyaluronan in mouse epidermis. J Histochem Cytochem (2011) 0.83
In silico analysis identifies a novel role for androgens in the regulation of human endometrial apoptosis. J Clin Endocrinol Metab (2011) 0.83
Regulation of cancer stem cells by p53. Breast Cancer Res (2008) 0.83
deltaNp63 has a role in maintaining epithelial integrity in airway epithelium. PLoS One (2014) 0.83
Li-Fraumeni syndrome with simultaneous osteosarcoma and liver cancer: increased expression of a CD44 variant isoform after chemotherapy. BMC Cancer (2012) 0.83
Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53. Cell Death Dis (2015) 0.82
Distinct Intracellular Domain Substrate Modifications Selectively Regulate Ectodomain Cleavage of NRG1 or CD44. Mol Cell Biol (2015) 0.82
Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin. J Invest Dermatol (2011) 0.82
ROS-DET: robust detector of switching mechanisms in gene expression. Nucleic Acids Res (2011) 0.82
CD44S-hyaluronan interactions protect cells resulting from EMT against anoikis. Matrix Biol (2015) 0.81
Hyaluronan as a therapeutic target in human diseases. Adv Drug Deliv Rev (2015) 0.81
Antitumor mechanisms when pRb and p53 are genetically inactivated. Oncogene (2014) 0.81
Regulation of stem cell plasticity: mechanisms and relevance to tissue biology and cancer. Mol Ther (2012) 0.81
Inside-out Regulation of Ectodomain Cleavage of Cluster-of-Differentiation-44 (CD44) and of Neuregulin-1 Requires Substrate Dimerization. J Biol Chem (2015) 0.81
Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma. Oncotarget (2013) 0.81
Cancer stem cell metabolism: a potential target for cancer therapy. Mol Cancer (2016) 0.80
Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors. Oncotarget (2015) 0.80
Cancer stem cells in breast cancer. Cancers (Basel) (2011) 0.80
The network of pluripotency, epithelial-mesenchymal transition, and prognosis of breast cancer. Breast Cancer (Dove Med Press) (2015) 0.80
A rapid, automated surface protein profiling of single circulating exosomes in human blood. Sci Rep (2016) 0.80
P53 Is Involved in a Three-Dimensional Architecture-Mediated Decrease in Chemosensitivity in Colon Cancer. J Cancer (2016) 0.79
Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes. Cell Cycle (2014) 0.79
α6 Integrin and CD44 enrich for a primary keratinocyte population that displays resistance to UV-induced apoptosis. PLoS One (2012) 0.79
Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress. PLoS One (2013) 0.79
TSPAN12 is a critical factor for cancer-fibroblast cell contact-mediated cancer invasion. Proc Natl Acad Sci U S A (2014) 0.79
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
Creation of human tumour cells with defined genetic elements. Nature (1999) 16.47
p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature (1999) 14.38
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature (1999) 13.21
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell (2006) 11.85
Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev (2001) 11.25
CD44 is the principal cell surface receptor for hyaluronate. Cell (1990) 11.01
DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell (2006) 9.47
CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol (2003) 9.13
p53 regulates mitochondrial respiration. Science (2006) 9.06
The antioxidant function of the p53 tumor suppressor. Nat Med (2005) 7.57
p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell (2007) 6.50
Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell (2008) 6.48
A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A (2001) 6.25
Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med (2006) 5.92
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol (2001) 5.82
The P53 pathway: what questions remain to be explored? Cell Death Differ (2006) 4.91
Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet (1990) 4.49
Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell (2007) 4.30
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res (2008) 3.98
p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol (2006) 3.37
p53 suppresses the self-renewal of adult neural stem cells. Development (2006) 3.35
CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood (1997) 2.71
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med (2006) 2.69
Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene (2001) 2.67
CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer (2008) 2.58
The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst (1996) 2.57
Biology of HER2 and its importance in breast cancer. Oncology (2001) 2.54
Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ (2003) 2.30
Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med (1997) 2.11
p53 down-regulates CHK1 through p21 and the retinoblastoma protein. Mol Cell Biol (2001) 1.93
Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem (1997) 1.86
Expression of CD44 is repressed in neuroblastoma cells. Mol Cell Biol (1991) 1.66
Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res (2002) 1.40
Isolation and identification of cancer stem-like cells from murine melanoma cell lines. Cell Mol Immunol (2007) 1.39
Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem (2001) 1.35
Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol (2000) 1.33
CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res (1997) 1.25
DeltaNp63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck. J Pathol (2007) 1.24
p130/E2F4 binds to and represses the cdc2 promoter in response to p53. J Biol Chem (2000) 1.22
Expression of the CD44v2-10 isoform confers a metastatic phenotype: importance of the heparan sulfate attachment site CD44v3. Cancer Res (2003) 1.13
Serial analysis of gene expression in normal p53 null mammary epithelium. Oncogene (2002) 1.07
E6/E7 oncogenes increase and tumor suppressors decrease the proportion of self-renewing neural progenitor cells. Oncogene (2006) 0.89
Expression of CD44 protein in renal cell carcinomas: association with p53 expression. Urol Oncol (2002) 0.85
Hallmarks of cancer: the next generation. Cell (2011) 140.01
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature (2009) 35.48
The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell (2004) 31.38
Reprogramming of human somatic cells to pluripotency with defined factors. Nature (2007) 30.84
Control of developmental regulators by Polycomb in human embryonic stem cells. Cell (2006) 28.21
Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature (2006) 25.90
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature (2007) 21.53
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67
Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet (2007) 15.46
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
Genome-wide map of nucleosome acetylation and methylation in yeast. Cell (2005) 15.08
Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell (2005) 15.06
Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell (2008) 14.80
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
A perspective on cancer cell metastasis. Science (2011) 13.31
Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell (2009) 13.02
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell (2008) 12.29
A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell (2010) 12.27
Control of pancreas and liver gene expression by HNF transcription factors. Science (2004) 12.05
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51
Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34
A progression puzzle. Nature (2002) 9.56
Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A (2004) 9.33
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res (2005) 8.69
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol (2007) 8.65
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol (2007) 8.11
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A (2004) 7.96
Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res (2008) 7.91
Ras oncogenes: split personalities. Nat Rev Mol Cell Biol (2008) 7.91
MicroRNAs and cancer: short RNAs go a long way. Cell (2009) 7.25
Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A (2008) 6.89
Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotechnol (2009) 6.76
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 6.67
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A (2010) 6.15
Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature (2003) 6.01
The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res (2005) 5.93
Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol (2011) 5.57
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A (2011) 5.53
Modelling the molecular circuitry of cancer. Nat Rev Cancer (2002) 5.43
Identification of molecular apocrine breast tumours by microarray analysis. Oncogene (2005) 5.27
Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A (2007) 5.24
Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev (2009) 5.21
Cancer stem cells: mirage or reality? Nat Med (2009) 5.20
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07
The signals and pathways activating cellular senescence. Int J Biochem Cell Biol (2004) 5.00
Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med (2004) 4.98
Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature (2009) 4.93
Rules for making human tumor cells. N Engl J Med (2002) 4.84
Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol (2010) 4.80
Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell (2011) 4.79
Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol (2002) 4.77
Slug and Sox9 cooperatively determine the mammary stem cell state. Cell (2012) 4.77
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet (2005) 4.70
Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle (2006) 4.67
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature (2002) 4.56
Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell (2012) 4.51
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc (2009) 4.50
A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst (2006) 4.44
Short RNAs are transcribed from repressed polycomb target genes and interact with polycomb repressive complex-2. Mol Cell (2010) 4.36
Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell (2007) 4.30
Species- and cell type-specific requirements for cellular transformation. Cancer Cell (2004) 4.25
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 4.19
Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell (2005) 4.14
Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol (2012) 3.98
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med (2007) 3.96